No Longer Just Looking under the Lamppost**Previously presented at the annual meeting of The American Society of Human Genetics, in Salt Lake City, on October 28, 2005.  by Collins, Francis S.
www.ajhg.org The American Journal of Human Genetics Volume 79 September 2006 421
2005 WILLIAM ALLAN AWARD ADDRESS
No Longer Just Looking under the Lamppost*
Francis S. Collins
From the National Human Genome Research Institute, National Institutes of Health, Bethesda
Address for correspondence and reprints: Dr. Francis S. Collins, National Human Genome Research Institute, National Institutes of Health, Building
31, Room 4B09, 31 Center Drive, Bethesda, MD 20892-6050. E-mail: fc23a@nih.gov
* Previously presented at the annual meeting of The American Society of Human Genetics, in Salt Lake City, on October 28, 2005.
Am. J. Hum. Genet. 2006;79:421–426.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7903-0003$15.00
Francis S. Collins
It is an honor to be receiving this award from a Society
for which I have the greatest affection and admiration.
There are many friends, former students, post-docs, and
colleagues whom I would love to acknowledge, but I won’t
be able to in these brief remarks. I would, however, like
to recognize and thank one person, and that’s my wife,
Diane Baker, a long-term member of this Society. Her stal-
wart support over the many bumps in the road the last
few years has never wavered and is deeply appreciated.
This Society has meant a great deal to me in the course
of the last 27 years. I started out as a physical chemist,
did a right turn into medicine, and then discovered ge-
netics as a promising area of medicine that was appealing
to somebody with a quantitative sense. But there weren’t
a lot of role models for me to observe, because, in those
days, medical genetics was not a ﬁeld that was widely
represented, particularly in internal medicine, which was
my clinical choice. So, I came to the meeting of the Amer-
ican Society of Human Genetics (ASHG) for the ﬁrst time
in Vancouver in 1978. (At that time, I was a junior resident
in internal medicine in North Carolina.) I will always trea-
sure that experience—and I hope that those of you at-
tending this meeting for the ﬁrst time will feel the same
excitement and exhilaration that I experienced on that
amazing trip 27 years ago.
It was a little different then: there were only ∼500 peo-
ple at the meeting. The ﬁrst afternoon, Y. W. Kan stood
up and described how he and Andre´e Dozy had identiﬁed
a particular restriction fragment–length polymorphism
(RFLP) that was associated with the presence of the sickle
mutation. They essentially described human linkage dis-
equilibrium and how it could be used for diagnostics.
Wow, that was exciting! In that same session, Mark Skol-
nick talked about how the use of RFLPs might be gener-
alized. Of course, that concept then emerged later on in
a famous paper1 that laid the groundwork for mapping
human disease genes by linkage, even when you didn’t
know what the function of the gene was. That became
the ﬁrst step in positional cloning.
Then Uta Francke, later to be one of my most signiﬁ-
cant mentors when I was a fellow in genetics at Yale, de-
scribed how she had been able to stretch chromosomes
out, to look at extended, high-resolution bandingpatterns
to detect small deletions and inversions that otherwise
had escaped detection. Pretty impressive stuff, all in one
afternoon!
More than that, there were role models in great abun-
dance at the ASHG meeting, including Lee Rosenberg and
many others. And some of them were even internists,
which gave me conﬁdence that this pathway was viable.
That really clinched my decision to become a medical ge-
neticist—and the ASHG meeting has reinforced that de-
cision every year that I attend. I’ve only missed one meet-
ing in 28 years.
I went on to become a genetics fellow at Yale, under the
able mentorship of Lee Rosenberg, as the department chair,
and Sherm Weissman, as my research supervisor. From the
perspective of a genetics fellow in 1981, there were a lot
of exciting things going on, but there were also some stiff
challenges that lay ahead. Recombinant DNA had come
along, making it possible to clone and study humangenes.
DNA sequencing was possible, although, in those days, we
did it with radioactive isotopes. It was not for the faint-
hearted to be involved in a laboratory that did a lot of
this stuff, because your Geiger counter was always going
off when it wasn’t supposed to—especially in Sherm’s lab!
We also had lots of clinical information in 1981 about
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medical genetic conditions that Victor McKusick had cat-
alogued. But, for most of those conditions, the speciﬁc
gene mutation remained unknown. A few disease genes,
such as that for hemophilia, were being cloned because
something was known about the functional consequence
of the gene mutation—allowing one to work backward
from the protein to the gene. But that knowledge wasn’t
available for most genetic disorders. And to be forced to
take a candidate-gene approach for these thousands of
disorders was generally not very rewarding. That brings
me to my metaphor for today’s presentation.
The metaphor relates to the story of a person who re-
alizes he has lost his keys after spending a few too many
hours at the bar. Looking up and down the dark street, he
decides to focus his search under the single lamppost. His
friends come along and inquire, “So, what’s the problem?”
He responds, “I’ve lost my keys.” And they say, “Well, why
are you just looking in this one place?” And he says, “It’s
where the light is.”
That’s the same situationwe faced in themid-1980swhen
trying to ﬁnd the genes for most Mendelian conditions.
We really desperately wanted to understand them, but we
lacked enough biological or biochemical information to
be able to know where to look. That challenge inspired a
host of people to develop a new strategy, which we now
call “positional cloning.”
As a fellow at Yale, I developed a method called “chro-
mosome jumping” that allowed one to cross chromoso-
mal regions in jumps of 100 kb or so. When I became an
assistant professor at the University of Michigan in 1984,
I looked for a place to apply this to a human genetic dis-
ease. Several conditions seemed particularly appealing:
cystic ﬁbrosis (CF), Huntington disease, and neuroﬁbro-
matosis. But, at that point in 1984, only one of those,
Huntington disease, had been mapped.2 This was the ﬁrst
success of RFLPmapping; later, of course, there weremany
hundreds more.
The focus of my own small laboratory was to try to jump
from a linked marker to the actual disease gene. Ultimate-
ly, CF, which I ﬁrst encountered as a clinical disorderwhile
serving as an internal medicine resident, became a very
appealing target. Here was a disease that was particularly
common and that caused a great deal of suffering and early
death. Despite the advances that had occurred in man-
agement of CF over the course of the preceding decades,
there was still little known about its molecular basis.With-
out knowing the nature of the gene that was responsible,
it was hard to know how research could move forward.
As a ﬁrst step, the CF gene needed to be mapped. That
breakthrough was announced, exactly 20 years ago, at the
1985 ASHG meeting, also in Salt Lake City.3
In short order, the candidate interval was reduced by
linkage analysis to ∼2 million base pairs on chromosome
7, between two ﬂanking markers. But there were no ad-
ditional clues to help narrow that daunting interval.
Tackling a problem of this difﬁculty in the 1980s was a
high-risk undertaking. I found myself trying to defend
why my own small laboratory was foolish enough to take
on such a hard problem. Months passed with little pro-
gress. I tried to come up with metaphors about how hard
this was, in order to explain to colleagues why we hadn’t
succeeded yet. I even went to a local farm in Ann Arbor
to have my picture taken holding a sewing needle while
sitting in a haystack.
But what ﬁnally led to success was meeting up with Lap-
Chee Tsui’s group in Toronto and deciding, at the 1987
ASHG meeting, that our two groups would work together.
The energy generated by the complementary nature of our
approaches ultimately allowed the crossing of an unprec-
edented amount of genomic territory.
Jumping and walking across 400 kb, we encountered a
large gene with 24 exons. Deﬁning the anatomy of this
gene now seems trivial, but, in those days, it was quite a
challenge. Ultimately, we became convinced that the de-
letion of just three base pairs—CTT—is responsible for
∼70% of the causative alleles for CF. This is the DF508
mutation.4 Jack Riordan, Lap-Chee, and I celebrated by
sipping on Canadian whiskey in coffee cups in Lap-Chee’s
ofﬁce that summer of 1989.
Although the search for the CF gene was ultimately suc-
cessful, it was enormously frustrating along the way. It
took years of effort and a lot of resources, both in terms
of intellectual capital and ﬁnancial capital, to ﬁnd this
one gene. If we were going to extrapolate such efforts to
the hundreds or thousands of disease-gene targets that one
would like to see successfully identiﬁed, we had to have
better tools. In this way, I think the CF gene discovery
served as an additional impetus for the genome project to
get under way. Finding the CF gene proved that positional
cloning could work but also demonstrated that more-ef-
ﬁcient methods would be needed if we were going to see
these discoveries occur on a larger scale.
I was a strong supporter of the Human Genome Project,
but I never expected to lead it. It was with some trepida-
tion, therefore, that I came to the National Institutes of
Health (NIH) to direct the U.S. genome effort, beginning
in 1993. I will not dwell on that experience, because you’ve
heard much of that before. But I will have to say what a
marvelous group of scientists I had the privilege of work-
ing with. We produced a draft sequence of the human
genome in 2000, published an analysis of that draft in
2001,5 and went on to ﬁnish the sequence in April of
2003,6 2 years ahead of schedule.
The genome sequence lit up the whole street—no more
just looking under the lamppost. This provided the oppor-
tunity for people chasing down Mendelian-disease genes
to be able to search through the whole genome swiftly
and efﬁciently. What we labored for years to do with CF
could now be essentially accomplished by a single grad-
uate student in a matter of a few days. The results were
spectacular: today, genes have been identiﬁed for 12,000
Mendelian conditions.
But that is not the end of the story. There still are plenty
of rare Mendelian traits for which we do not have answers.
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Linkage may have mapped the gene, but the interval is
still too large, and the candidate genes have not panned
out. What then?
To respond to this, the National Human Genome Re-
search Institute (NHGRI) has mounted a new program.
We will devote a signiﬁcant component of our prodigious
sequencing capacity (roughly 150 billion bp per year) to
medical applications. We are seeking your advice about
interesting targets—including both Mendelian and non-
Mendelian conditions—where large-scale sequencing could
push the ﬁeld forward.
But what about the genetics of common disease? De-
spite all the tools produced in 2003 by the Genome Pro-
ject, Joel Hirschhorn, who has kept track of the reporting
and validation of genetic variants associated with com-
mon disease, told me earlier today that he only believes
in about a dozen gene variants that cause susceptibility
to common disease like diabetes. While that number is a
lot better than 5 years ago, we want to make this list grow
faster. The problem is difﬁcult, however, because linkage,
which has been such a successful workhorse forMendelian
conditions, is woefully underpowered when it comes to
polygenic conditions. Risch and Merikangas showed us
almost 10 years ago that association would be amore pow-
erful approach.7 The problem, of course, is that compre-
hensive association studies for complex diseases, such as
diabetes, have not really been possible in the past—you
were forced to pick candidate genes, and you were usually
wrong.
Does this sound familiar? We’re back in that same
“searching under the lamppost” scenario. Clearly, we need
a more systematic way of approaching this complex dis-
ease–gene search that doesn’t force you to know the an-
swer before you start.
That’s what the International HapMap Project has been
all about. This is an organized production effort that has
been carried out by a wonderfully dedicated group of sci-
entists from six countries. By February 2005, we had com-
pleted a Phase 1 map of 11 million SNPs, genotyped across
270 DNA samples from four different populations. Phase
2, including 4 million SNPs, was completed last sum-
mer, and the analysis of Phase 1 was published in October
2005 in Nature.8 Using the HapMap resource, you can ef-
fectively survey the entire genome for evidence of asso-
ciation with ∼300,000 SNPs for European or Asian samples
and ∼500,000 for African samples.
Some of the early successes with HapMap have already
been reported in publications or at this meeting. Perhaps
none is more impressive than the discovery that a poly-
morphism in the complement factor H gene contributes
approximately half of the attributable risk for age-related
macular degeneration.9
As another example, type 2 diabetes (T2DM) is one of
those conditions that all of us hope will greatly beneﬁt
from the availability of HapMap. Working with my col-
league Mike Boehnke and several other collaborators
around the world, we have been trying for 10 years to
track down susceptibility variants for this common dis-
order, and it is a challenging problem, to be sure.
The Finland-U.S. Investigation of noninsulindependent
diabetes mellitus (FUSION) study has managed to collect
thousands of DNA samples from affected and unaffected
individuals in Finland. We have applied the strategy of
linkage analysis to 1700 affected sib pairs across the ge-
nome. There have been a few interesting linkage signals,
particularly on chromosomes 6, 11, 14, and 20. With the
availability of high-density SNP maps, we were recently
able to follow up the chromosome 20 signal, and were
able to identify associated variants that are near the P2
promoter of the HNF-4a gene.10 Loss-of-function muta-
tions in this gene cause maturity-onset diabetes of the
young, but we had previously excluded its role in T2DM.
Now, we know that our original conclusion was incorrect
because we were just looking at the coding region, and
the associated variants lie far upstream. Another group
led by Alan Permutt in St. Louis independently came up
with the same ﬁnding in a group of Ashkenazi Jews,11 and
several other teams have also now conﬁrmed this same
association.
While this was a gratifying outcome, we are certain that
other important susceptibility genes were missed in our
ﬁrst phase of linkage analysis. So the next step of whole-
genome association studies for T2DM is anticipated with
great excitement. In fact, several groups around the world
that are studying T2DM recently agreed that this would
be a great time to collaborate and pool their data as we
move into this new phase.
How successful will this strategy be? We don’t really
know. But I’ve recently made a wager with my former
chairman, Tom Gelehrter. Tom is a professional cynic; I’m
an incorrigible optimist. So, we’re going to see who’s right
this time. I’m betting that, by the time of the ASHG meet-
ing in 2008, whole-genome association studies will have
led to the discovery of at least four validated—not just
guessed at—susceptibility variants for at least ﬁve com-
mon polygenic diseases. I’ve asked Joel Hirschhorn to be
the referee. And, of course, the wager is substantial: one
beer of the winner’s choosing.
If I’m even close to right, the Congress had better get
busy. That’s because we will then be in a circumstance
where risk-predicting genotypes will be available for lots
of people, initially as part of research and ultimately as
part of clinical care. If that information can be used against
someone in health insurance or the workplace, then we
have not lived up to our social responsibility to prevent
that kind of discriminatory misuse. A current bill (S.306/
HR.1227) currently under consideration in the United
States Congress would solve this. The ASHG has been very
effective in supporting that bill, but it will take lots of
grassroots support to get it over the ﬁnish line.
So genomics holds the promise of revolutionizing un-
derstanding of disease and even leading to risk prediction.
But what about therapy? Let me tell you a story about a
rare-disease research project in my own lab that is leading
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toward treatment at a surprising pace. I ﬁrst encountered
this condition when I was a clinical fellow at Yale. During
my ﬁrst week, I was told: “You’re pretty lucky, because
you’re going to be assigned our most famous patient.”
That patient was Meg Casey. Meg carried a diagnosis of
Hutchinson-Gilford progeria syndrome, the most dramatic
form of premature aging—although, at the age of 23, Meg
had clearly lived longer than most do with progeria. Most
children with this disorder die of cardiovascular compli-
cations—usually heart attack or stroke—at about age 12
or 13.
Meg was a feisty advocate for the disabled. She could
disarm anybody who took her less than seriously because
of her diminutive height and high-pitched voice, by un-
leashing the most impressive stream of sailor’s language
that you can imagine. She almost single-handedlyworked
to make Milford, CT, accessible to the handicapped. Meg
was also absolutely charming and spunky. It was a great
honor to take care of her for those 3 years.
Because of Meg, I got very interested in progeria and
wondered why more wasn’t known about this condition.
The problem was that the disease never recurs in families.
How could a geneticist start chasing after the gene when
there were no multiplex pedigrees?
Sadly, Meg died about 3 or 4 years after I left Yale, and
I stopped thinking much about progeria. Then, about 5
years ago, I met a boy named Sam who has progeria in
the classic form. Sam’s parents are both physicians; after
learning of their son’s diagnosis, they started the Progeria
Research Foundation. They came to me asking for advice
about how to get scientists interested in working on this
problem. After a few conversations, I was hooked! A fear-
less post-doc in my lab, Maria Eriksson, agreed to take on
the task of trying to ﬁnd the gene for this disorder, even
though the tools to do so, lacking pedigrees, were pretty
limited.
Through a combination of hard work and serendipity,
Maria was able to show that the gene had to be on the
long arm of chromosome 1. That achievement was almost
a course in human genetics, involving a host of unex-
pected phenomena, such as somatically acquired unipa-
rental segmental isodisomy. Ultimately, the locationof the
gene was narrowed to ∼6 Mb, within which was located
an attractive candidate gene: the gene for lamin A. This
gene had already been implicated in six other genetic dis-
eases, with the phenotype apparently depending onwhere
in the coding region the mutation fell. One of those dis-
eases, mandibuloacral dysplasia, had enough similarities to
progeria that the two disorders were occasionally confused.
So, the lamin A gene seemed like a very good candidate
for sequencing. Maria’s efforts were quickly rewarded by
ﬁnding that 95% of patients with classic progeria had a
single-nucleotide substitution of a T instead of a C in the
third base of codon 608.12 We found one other patient
with a mutation just 2 bp upstream in the same exon. In
every instance in which we had access to parental DNA,
the parents were normal, so these were sporadic de novo
mutations.
We were puzzled, however, when we looked carefully at
the genetic code. The mutation converted a GGC codon
to a GGT codon; both code for glycine. By most deﬁni-
tions, this would be called a silent mutation. But from a
geneticist’s perspective, this recurrent de novo point mu-
tation had to be the cause.
A bit of reﬂection upon the experience of working on
thalassemia with Bernie Forget and Sherm Weissman 20
years earlier, however, helped me realize that there was
something else about this sequence that looked familiar:
the normal sequences of codons 606–608 look quite a lot
like a splice donor, and that similarity increases if either
one of these two progeria mutations occurs. So, Maria and
I postulated that themutations created a functional splice-
donor sequence in the middle of exon 11, causing skip-
ping over the rest of that exon, leaving out 150 bp and
deleting 50 aa. The stop codon for lamin A is located just
inside exon 12, so the abnormal splice form would still
produce a protein with the correct C terminus.
Fortunately for us, we had fallen into an area of exten-
sive prior investigation by cell biologists. Lamin A is a
major structural protein that holds the nucleus in its ap-
propriate shape. It is located just under the nuclear mem-
brane and interacts with a host of other proteins, some
of which cause genetic diseases like Emery-Dreifuss mus-
cular dystrophy. In addition, some fraction of lamin A
ﬂoats around in the nucleoplasm and has been shown to
interact with certain transcription factors.
Noting this, we looked closely at the nuclei of cultured
skin ﬁbroblasts from children with progeria. Our efforts
were rewarded. In early passages, progeria ﬁbroblasts have
nuclei that look rather normal. But, as the cells go through
later passages, the nucleus becomes quite abnormal. Nu-
clear blebbing and herniation are eventually observed for
the majority of cells, and their morphology can be quite
bizarre and dramatic. Eventually, this leads to premature
death of the cells, although we are still not quite sure by
what mechanism this occurs.
So, how does this protein that is missing 50 aa cause
such havoc? Again, we were much beneﬁted by all the
work that had been done by biochemists and cell biolo-
gists to deﬁne the normal processing of this particular
protein.13 Lamin A has a CAAX box at its C terminus,
which serves as a recognition site for the farnesyltrans-
ferase enzyme. A farnesyl lipid group is added to the cys-
tine, and then an additional enzyme cleaves off the last
3 aa, which happen to be serine, isoleucine, and methio-
nine. Then, there is an additional processing step cata-
lyzed by an enzyme ﬁrst identiﬁed in yeast but that has
a homologue in humans called “ZMPSTE24.” This enzyme
cleaves off 15 aa of the C terminal fragment (including
the farnesyl tail), releasing mature lamin A.
Farnesyl groups tend to anchor proteins in cell mem-
branes, so one might guess that pre–lamin A is initially
anchored in the nuclear membrane after this hydrophobic
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lipid is added. However, to function properly in the scaf-
fold, lamin A needs to be liberated from the membrane
so it can ﬂoat freely and assemble into this multipro-
tein complex. In progeria, the 50-aa deletion removes the
recognition site for that internal proteolytic cleavage by
ZMPSTE24. That leaves the protein permanently farnesyl-
ated and unable to escape from the membrane, acting like
a “tar baby” to drag along with it all of the other com-
ponents of the lamina.
This mechanistic hypothesis suggests an intervention.
If farnesylation is contributing to the progeria phenotype,
we might be able to block that pharmacologically. For-
tunately, drugs that might inhibit farnesylation have been
of great interest for 15 years, since the famous oncoprotein
ras is also farnesylated. Several drug companies have ex-
pended hundreds of millions of dollars in developing far-
nesyltransferase inhibitors (FTIs) that work well in vitro.
In fact, several of those have made it through animal test-
ing, and two of them are now in human phase 3 trials for
cancer and have shown a good safety proﬁle, including
some studies in children. Both Schering-Plough and John-
son & Johnson, the drug manufacturers, graciously agreed
to make their FTIs available.
In initial cell-culture experiments, I did not expect to
see an FTI work on progeria cells that already displayed
an abnormal nuclear morphology; I assumed these would
be irreversibly altered. But, in several different skin ﬁbro-
blast lines from progeria patients after various doses of an
FTI given over just 72 h, the correction of nuclear blebbing
was dramatic.14 This was a very exciting ﬁnding.
As a next step, we developed an animal model of pro-
geria by constructing a BAC transgenic mouse carrying
the human lamin A gene, with the G608G mutation in-
troduced by recombineering. This mouse has a very in-
teresting phenotype, with much similarity to the human
disease.15 The large arteries of the G608G transgenic show
progressive dropout of vascular smooth-muscle cells in the
arterial media. This is remarkably similar to the cardio-
vascular pathology seen in children with progeria. We are
now treating these mice with oral FTIs to see whether we
can actually prevent these pathologic ﬁndings. If all goes
well, we could initiate a clinical trial for children with
progeria next year.
We’ve also been interested in other variant forms of
progeria, since not every case looks exactly like Sam, who
has the classic form. So, we obtained DNA samples from
the various repositories and sequenced the lamin A gene
to see what we could ﬁnd. Sure enough, we found a couple
of other samples that had different mutations in lamin A.
One interesting case with longer survival turned out to
have two nonsynonymous coding mutations, essentially
a recessive form.When I reviewed the clinical information
on this case, I recognized my own words. This was my
patient, Meg Casey.
I’d forgotten that, encouraged by my mentors at Yale,
I had obtained a blood sample from Meg 20 years earlier
and had sent it into the repository, hoping that, some day,
somebody might discover why this wonderful young wo-
man had this terrible disease. I never dreamed this would
come full circle.
In closing, I’d like to share a few of the many lessons
learned from my 27 years of coming to ASHG meetings
and being part of this remarkable and rewarding ﬁeld of
medical genetics.
First, collaboration is critical to making progress. Our
most important collaborators will always be our patients.
But there are many others, especially students and post-
docs. I’ve had awonderful opportunity toworkwith amaz-
ingly talented young scientists in this category. They are
the real heroes of discovery. They’re the ones who are
doing the experiments, taking the risks, making incredible
observations. But collaborators in other disciplines are also
critical, and never more so than now; nobody can know
everything we need to know to take advantage of the cur-
rent opportunities in genetics, genomics, computational
biology, physiology, and medicine. Taking collaboration
even further, big projects, such as those I’ve had the priv-
ilege of being involved in, need big teams. It’s been amaz-
ing to see what can happen then—with the sequencing
projects, with HapMap, with ENCODE, and with many
others. But do not be disheartened if you’re not part of
one of those big teams. You still have the chance to use
all of the data from these big projects, because we’ll con-
tinue to make sure the data end up in the public domain.
And it is the individual scientist with creative ideas, em-
powered by these new tools, who will continue to make
most of the big breakthroughs.
A second lesson: It is very easy in scientiﬁc research to
stay in your comfort zone. For many of us, our comfort
zone has been basic science. But I want to encourage you
to go beyond that comfort zone into translational appli-
cations if you see an opportunity to do so, as we are now
doing in progeria. We could have continued to just study
the cell biology and genetics of lamin A, but if we have
the chance to bring this knowledge to the clinic and offer
a potentially useful treatment to children with this dis-
ease, that ought to be our highest priority. The NIH is
putting additional support systems in place to make this
possible. But it will take determination and risk taking to
bring together the cultures of basic and clinical research.
This should be a high priority for our ﬁeld.
A third lesson is the need for all of us to accept a role
in social responsibility—whether working to solve the
problem of genetic discrimination, taking part in the im-
portant debates about what limits there should be on ap-
plications of genetics, or dealing with the potentially ex-
plosive topic of race and genetics. There may have once
been a time when a scientist could go in the lab, close the
door, and say “Those issues are somebody else’s problem.”
But that time has passed for genetics.
A ﬁnal lesson: Don’t settle for looking under lampposts
anymore. A remarkable and growing list of resources is
making it possible to approach research problems with a
new and ambitious goal of comprehensiveness. Develop
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a “genome attitude!” Now, in our searches for the “lost
keys,” we have all of the brightness of the “street” laid
out in front of us. Let’s make the most of that.
Friends and colleagues, we are indeed privileged towork
in a ﬁeld that holds such great promise for medicine—
perhaps the greatest since the introduction of antibiotics.
Let us resolve together to make good on this historic op-
portunity, for the beneﬁt of all the world’s peoples.
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